Citeline

Expedite trial enrollment by focusing only on potential participants who precisely fit the protocol for your trial with Citeline PatientMatch.

Citeline PatientMatch integrates real-world data to deliver custom-timed alerts upon patients receiving lab or biomarker results that might make them eligible for a study.

Pharma had its strongest year on record for new drug launches in 2025, and the order at the front changed. For the first time, China overtook the US as the leading country for first launches, 47 to 43. Download the Pole Position report to see who reached the podium and which drugs are tipped to follow in 2026.

Who's leading pharma R&D depends on where you look. AstraZeneca added more new candidates to its pipeline than any other company in 2025, while Jiangsu Hengrui led all companies in launches. Download Citeline's Pole Position report, built on Pharmaprojects and Trialtrove data, to see who is setting the pace at every stage of the race.

Every sponsor wants to hit enrollment on time, yet 85% of trials miss their target and recruitment can take up to 20% of a Phase III budget. A new Citeline survey of 144 physicians highlights a lever many teams overlook: willing physicians refer only when they can find and trust your trial information. Download the white paper to see how clearer listings help keep your enrollment on track.

Clinical trial activity faced significant headwinds in 2025, with completed studies declining 11% year over year. Yet beneath the surface, success rates improved, positive pivotal trials increased and late-stage momentum continued in key therapeutic areas such as oncology and metabolic disease. Explore the data, trends and sponsor performance shaping the future of clinical development in Citeline’s Annual Completed Clinical Trials Report.